Occurrence and removal of transformation products of PPCPs and illicit drugs in wastewaters: A review

Science of the Total Environment

Volumn 505, Issue , 2015, Pages 905-926

  Evgenidou, Eleni N ^a   Konstantinou, Ioannis K ^b   Lambropoulou, Dimitra A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Illicit drugs; Occurrence; PPCPs; Removal; Transformation products; Wastewaters

Indexed keywords

WASTEWATER;

ILLICIT DRUG; OCCURRENCE; PPCPS; TRANSFORMATION PRODUCTS;

REMOVAL;

ACETYLSALICYLIC ACID; AGENTS AFFECTING LIPID METABOLISM; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; CHEMICAL COMPOUND; CLOFIBRATE; CONTRAST MEDIUM; CYTOSTATIC AGENT; DICLOFENAC; DRUG; DRUG METABOLITE; ERYTHROMYCIN; ESTROGEN DERIVATIVE; ETOFIBRATE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ILLICIT DRUG; PHARMACEUTICAL AND PERSONAL CARE PRODUCT; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SALICYLIC ACID; TRANSFORMATION PRODUCT; UNCLASSIFIED DRUG; SEWAGE; STREET DRUG; WASTE WATER; WATER POLLUTANT;

DRUG; METABOLITE; REACTION KINETICS; TOXICITY; WASTE FACILITY; WASTEWATER; WATER TREATMENT;

AQUATIC ENVIRONMENT; BIOSOLID; BIOTRANSFORMATION; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); ECOTOXICOLOGY; EFFLUENT; ENVIRONMENTAL MONITORING; ENVIRONMENTAL RISK ASSESSMENT; HUMAN; INFLUENT; MASS SPECTROMETRY; NONHUMAN; NONTARGET SCREENING; PHYSICAL CHEMISTRY; REVIEW; RISK ASSESSMENT; SLUDGE; SUSPECT SCREENING; TARGET ANALYSIS; TOXICITY TESTING; WASTE COMPONENT REMOVAL; WASTE WATER; WASTE WATER TREATMENT PLANT; WATER POLLUTANT; ANALYSIS; CHEMISTRY; SEWAGE;

ENVIRONMENTAL MONITORING; RISK ASSESSMENT; SEWAGE; STREET DRUGS; WASTE DISPOSAL, FLUID; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84909953526     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2014.10.021     Document Type: Review

References (223)

1. Bahlmann A., Brack W., Schneider R.J., Krauss M. Carbamazepine and its metabolites in wastewater: analytical pitfalls and occurrence in Germany and Portugal. Water Res 2014, 57:104-114.
2. Barclay V.K.H., Tyrefors N.L., Johansson I.M., Pettersson C.E. Chiral analysis of metoprolol and two of its metabolites, a-hydroxymetoprolol and deaminated metoprolol, in wastewater using liquid chromatography-tandem mass spectrometry. J Chromatogr 2012, 1269:208-217.
3. Baselt R.C. Disposition of toxic drugs and chemicals in man 2004, Biomedical Publications, Foster City, California, USA.
4. Batt A.L., Mitch S.K., Lazorchak M.J. Analysis of ecologically relevant pharmaceuticals in wastewater and surface water using selective solid-phase extraction and UPLC-MS/MS. Anal Chem 2008, 80:5021-5030.
5. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 1998, 13:S35-S43.
6. Behera S.K., Kim H.W., Oh J.-E., Park H.-S. Occurrence and removal of antibiotics, hormones and several other pharmaceuticals in wastewater treatment plants of the largest industrial city of Korea. Sci Total Environ 2011, 409:4351-4360.
7. Bendz D., Paxéus N.A., Ginn T.R., Loge F.J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. J Hazard Mater 2005, 122:195-204.
8. Benfield P., Heel R.C., Lewis S.P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986, 32:481-508.
9. Benotti M.J., Brownawell B.J. Distributions of pharmaceuticals in an urban estuary during both dry- and wet-weather conditions. Environ Sci Technol 2007, 41:5795-5802.
10. Berset J.D., Brenneisen R., Mathieu C. Analysis of licit and illicit drugs in waste, surface and lake water samples using large volume direct injection high performance liquid chromatography-electrospray tandem mass spectrometry HPLC-MS/MS. Chemosphere 2010, 81:859-866.
11. Bijlsma L., Sancho J.V., Pitarch E., Ibáñez M., Hernádez F. Simultaneous ultra high pressure liquid chromatography-mass spectrometry determination of amphetamine like stimulants, cocaine and its metabolites, and a cannabis metabolite in surface water and urban wastewater. J Chromatogr A 2009, 1216:3078-3089.
12. Bijlsma L., Emke E., Hernández F., De Voogt P. Investigation of drugs of abuse and relevant metabolites in Dutch sewage water by liquid chromatography coupled to high resolution mass spectrometry. Chemosphere 2012, 89:1399-1406.
13. Bleeker E.A.J., Van der Geest H.G., Klamer H.J.C., De Voogt P., Wind E., Kraak M.H.S. Toxic and genotoxic effects of azaarenes: isomers and metabolites. Polycyclic Aromat Compd 1999, 13:191-203.
14. Boczar B.A., Forney L.J., Begley W.M., Larson R.J., Federle T.W. Characterization and distribution of esterase activity in activated sludge. Water Res 2001, 35:4208-4216.
15. Boix C., Ibáñez M., Zamora T., Sancho J.V., Niessen W.M.A., Hernández F. Identification of new omeprazole metabolites in wastewaters and surface waters. Sci Total Environ 2014, 468-469:706-714.
16. Boleda M.R., Galceran M.T., Ventura F. Trace determination of cannabinoids and opiates in wastewater and surface waters by ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr A 2007, 1175:38-48.
17. Bones J., Kevin V.T., Paull B. Using environmental analytical data to estimate levels of community consumption of illicit drugs and abused pharmaceuticals. J Environ Monit 2007, 9:701-707.
18. Bort R., Ponsoda X., Carrasco E., Gomez-Lechon M.J., Castell J.V. Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos 1996, 24:969-975.
19. Bort R., Ponsoda X., Carrasco E., Gómez-Lechón M.J., Castell J.V. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996, 24:834-841.
20. Boxall A.B.A., Sinclair C.J., Fenner K., Koplin D, Maund SJ Peer reviewed: when synthetic chemicals degrade in the environment. Environ Sci Technol 2004, 38:368-375.
21. Bradley P.M., Barber L.B., Kolpin D.W., McMahon P.B., Chapelle F.H. Biotransformation of caffeine, cotinine, and nicotine in stream sediments: implications for use as wastewater indicators. Environ Toxicol Chem 2007, 26:1116-1121.
22. Bramer S.L., Kallungal B.A. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers 2003, 8:187-203.
23. Breton H., Cociglio M., Bressolle F., Peyriere H., Blayac J.P., Hillaire-Buys D. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B 2005, 828:80-90.
24. Bueno Martínez M.J., Agüera A., Gómez M.J., Hernando M.D., García-Reyes J.F., Fernández-Alba A.R. Application of liquid chromatography/quadrupole-linear ion trap mass spectrometry and time-of-flight mass spectrometry to the determination of pharmaceuticals and related contaminants in wastewater. Anal Chem 2007, 79:9372-9384.
25. Buerge I.J., Kahle M., Buser H.R., Muller M.D., Poiger T. Nicotine derivatives in wastewater and surface waters: application as chemical markers for domestic wastewater. Environ Sci Technol 2008, 42:6354-6360.
26. Buser H.-R., Poiger T., Muller M.D. Occurrence and environmental behaviour of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater. Environ Sci Technol 1999, 33:2529-2535.
27. Buth J.M., Grandbois M., Vikesland P.J., McNeill K., Arnold W.A. Aquatic photochemistry of chlorinated triclosan derivatives: potential source of polychlorodibenzo-p-dioxins. Environ Toxicol Chem 2009, 28:2555-2563.
28. Buth J.M., Ross M.R., McNeill K., Arnold W.A. Reprint of: removal and formation of chlorinated triclosan derivativesin wastewater treatment plants using chlorine and UV disinfection. Chemosphere 2011, 85:284-289.
29. Calza P., Debora F. Advanced mass spectrometry-based techniques for the identification and structure elucidation of transformation products of emerging contaminants. In. Transformation products of emerging contaminants in the environment: analysis, processes, occurrence, effects and risks 2014, 325-346. John Wiley and Sons Ltd. 1st ed. D.A. Lambropoulou, L.M.L. Nollet (Eds.).
30. Canosa P., Morales S., Rodriguez I., Rubi E., Cela R., Gomez M. Aquatic degradation of triclosan and formation of toxic chlorophenols in presence of low concentrations of free chlorine. Anal Bioanal Chem 2005, 383:1119-1126.
31. Canosa P., Rodriguez I., Rubi E., Negreira N., Cela R. Formation of halogenated by-products of parabens in chlorinated water. Anal Chim Acta 2006, 575:106-113.
32. Carlsson C., Johansson A., Alvan B., Bergman K., Kuhler T. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. Sci Total Environ 2006, 364:67e87.
33. Carretero I., Vadillo M., Laserna J.J. Determination of antipyrine metabolites in human plasma by solid-phase extraction and micellar liquid chromatography. Analyst 1995, 120:1729-1732.
34. Castiglioni S., Zuccato E., Crisci E., Chiabrando C., Fanelli R., Bagnati R. Identification and measurement of illicit drugs and their metabolites in urban wastewater by liquid chromatography-tandem mass spectrometry. Anal Chem 2006, 78:8421-8429.
35. Castiglioni S., Bagnati R., Melis M., Panawennage D., Chiarelli P., Fanelli R., et al. Identification of cocaine and its metabolites in urban wastewater and comparison with the human excretion profile in urine. Water Res 2011, 45:5141-5150.
36. Celiz M.D., Tso J., Aga D.S. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ Toxicol Chem 2009, 28:2473-2484.
37. Chee-Sanford J.C., Aminov R.I., Krapac I.J., Garriques-Jeanjean N., Mackie R.I. Occurrence and diversity of tetracycline resistance genes in lagoons and groundwater underlying two swine production facilities. Appl Environ Microbiol 2001, 67:1494-1502.
38. Cherny N.I., Baselga J., de Conno F., Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy. Init Ann Oncol 2010, 21:615-626.
39. Chiaia A.C., Banta-Green C., Field J. Eliminating solid phase extraction with large-volume injection LC/MS/MS: analysis of illicit and legal drugs and human urine indicators in U.S. wastewaters. Environ Sci Technol 2008, 42:8841-8848.
40. Chiaia-Hernandez A.C., Schymanski E.L., Kumar P., Singer H.P., Hollender J. Suspect and nontarget screening approaches to identify organic contaminant records in lake sediments. Anal Bioanal Chem 2014, [in Press]. 10.1007/s00216-014-8166-0.
41. Cruz-Morato C., Ferrando-Climent L., Rodriguez-Mozaz S., Barcelo D., Marco-Urrea E., Vicent Sarra M. Degradation of pharmaceuticals in non-sterile urban wastewater by Trametes versicolor in a fluidized bed bioreactor. Water Res 2013, 47:5200-5210.
42. Custodio J.B.A., Dinis T.C.P., Almeida L.M., Madeira V.M.C. Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem Pharmacol 1994, 47:1989-1998.
43. D'Ascenzo G., Di Corcia A., Gentili A., Mancini R., Mastropasqua R., Nazzari M., et al. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci Total Environ 2003, 302:199-209.
44. Dong Z., Senn D.B., Moran R.E., Shine J.P. Prioritizing environmental risk of prescription pharmaceuticals. Regul Toxicol Pharmacol 2013, 65:60-67.
45. Escher B.I., Fenner K. Recent advances in environmental risk assessment of transformation products. Environ Sci Technol 2011, 45:3835-3847.
46. Fatta-Kassinos D., Vasquez M.I., Kümmerer K. Transformation products of pharmaceuticals in surface waters and wastewater formed during photolysis and advanced oxidation processes - degradation, elucidation of byproducts and assessment of their biological potency. Chemosphere 2011, 85:693-709.
47. Feldmann D.F., Zuehlke S., Heberer T. Occurrence, fate and assessment of polar metamizole dipyrone residues in hospital and municipal wastewater. Chemosphere 2008, 71:1754-1764.
48. Ferrando-Climent L., Collado N., Buttiglieri G., Gros M., Rodriguez-Roda I., Rodriguez-Mozaz S., et al. Comprehensive study of ibuprofen and its metabolites in activated sludge batch experiments and aquatic environment. Sci Total Environ 2012, 438:404-413.
49. Ferrando-Climent L., Rodriguez-Mozaz S., Barceló D. Development of a UPLC-MS/MS method for the determination of ten anticancer drugs in hospital and urban wastewaters, and its application for the screening of human metabolites assisted by information-dependent acquisition tool IDA; in sewage samples. Anal Bioanal Chem 2013, 405:5937-5952.
50. Ferrer I., Thurman E.M. Identification of a new antidepressant and its glucuronide metabolite in water samples using liquid chromatography/quadrupole time-of-flight mass spectrometry. Anal Chem 2010, 82:8161-8168.
51. Fredheim O.M., Moksnes K., Borchgrevink P.C., Kaasa S., Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008, 52:879-889.
52. Gentili A., Perret D., Marchese S. Analysis of free estrogens and their conjugates in sewage and river waters by solid phase extraction then liquid chromatography-electrospray-tandem mass spectrometry. Chromatographia 2002, 56:25-32.
53. Gheorghe A., van Nuijs A., Pecceu B., Bervoets L., Jorens P.G., Blust R., et al. Analysis of cocaine and its principal metabolites in waste and surface water using solid-phase extraction and liquid chromatography-ion trap tandem mass spectrometry. Anal Bioanal Chem 2008, 391:1309-1319.
54. Ghoshdastidar A.J., Fox S., Tong A.Z. The presence of the top prescribed pharmaceuticals in treated sewage effluents and receiving waters in Southwest Nova Scotia, Canada. Environ Sci Pollut Res 2014, 10.1007/s11356-014-3400-z.
55. Gilart N., Cormack P.A.G., Marcé R.M., Fontanals N., Borrull F. Selective determination of pharmaceuticals and illicit drugs in wastewaters using a novel strong cation-exchange solid-phase extraction combined with liquid chromatography-tandem mass spectrometry. J Chromatogr A 2014, 1325:137-146.
56. Glassmeyer S.T., Furlong E.T., Koplin D.W., Cahill J.D., Zaugg S.D., Werner S.L., et al. Transport of chemical and microbial compounds from known wastewater discharges: potential use as indicators of human fecal contamination. Environ Sci Technol 2005, 39:5157-5169.
57. Golden R., Gandy J., Vollmer G. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol 2005, 35:435-458.
58. Goldstein J.A., Safe S.H. Mechanisms of action and structure-activity relationship for the chlorinated dibenzo-p-dioxins and related compounds. Halogenated biphenyls, terphenyls, naphthalenes, dibenzodioxins and related products 1989, 239-293. Elsevier, Amsterdam. R.D. Kimbrough, A.A. Jensen (Eds.).
59. Gómez M.J., Martínez Bueno M.J., Lacorte S., Fernández-Alba A.R., Agüera A. Pilot survey monitoring pharmaceuticals and related compounds in a sewage treatment plant located on the Mediterranean coast. Chemosphere 2007, 66:993-1002.
60. Gómez M.J., Sirtori C., Mezcua M., Fernández-Alba A.R., Agüera A. Photodegradation study of three dipyrone metabolites in various water systems: identification and toxicity of their photodegradation products. Water Res 2008, 42:2698-2706.
61. Gómez M.J., Gómez-Ramos M.M., Malato O., Mezcua M., Fernández-Alba A.R. Rapid automated screening, identification and quantification of organic microcontaminants and their main transformation products in wastewater and river waters using liquid chromatography quadrupole-time-of-flight mass spectrometry with an accurate-mass database. J Chromatogr A 2010, 1217:7038-7054.
62. Gómez-Ramos M., Pérez-Parada A., García-Reyes J.F., Fernández-Alba A.R., Agüera A. Use of an accurate-mass database for the systematic identification of transformation products of organic contaminants in wastewater effluents. J Chromatogr A 2011, 1218:8002-8012.
63. González-Mariño I., Quintana J.B., Rodríguez I., Cela R. Simultaneous determination of parabens, triclosan and triclocarban in water by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2009, 23:1756-1766.
64. González-Mariño I., Quintana J.B., Rodríguez I., Cela R. Evaluation of the occurrence and biodegradation of parabens and halogenated by-products in wastewater by accurate-mass liquid chromatography-quadrupole-time-of-flight-mass spectrometry LC-QTOF-MS. Water Res 2011, 45:6770-6780.
65. González-Mariño I., Quintana J.B., Rodríguez I., Sánchez-Méndez N., Cela R. Transformation of cocaine during water chlorination. Anal Bioanal Chem 2012, 404:3135-3144.
66. Gros M., Rodríguez-Mozaz S., Barceló D. Fast and comprehensive multi-residue analysis of a broad range of human and veterinary pharmaceuticals and some of their metabolites in surface and treated waters by ultra-high-performance liquid chromatography coupled to quadrupole-linear ion trap tandem mass spectrometry. J Chromatogr A 2012, 1248:104-121.
67. Gulkowska A., Leung H.W., So M.K., Taniyasu S., Yamashita N., Yeung L.W.Y., et al. Removal of antibiotics from wastewater by sewage treatment facilities in Hong Kong and Shenzhen, China. Water Res 2008, 42:395-403.
68. Halling-Sørensen B., Nielsen N., Lansky P.F., Ingerslev F., Hansen L., Lützhøft H.C., et al. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36:357-394.
69. Haufroid V., Lison D. Urinary cotinine as a tobacco smoke exposure index: a mini review. Int Arch Occup Environ Health 1998, 71:162-163.
70. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in aquatic environment: a review of recent research data. Toxicol Lett 2002, 131:5-17.
71. Heberer T., Stan H.-J. Determination of clofibric acid and N-phenylsulfonyl;-sarcosine in sewage, river and drinking water. Int J Environ Anal Chem 1997, 67:113-124.
72. Henschel K., Wenzel A., Diedrich M., Fliedner A. Environmental hazard assessment of pharmaceuticals. Regul Toxicol Pharmacol 1997, 25:220-225.
73. Hirsch R., Ternes T., Haberer K., Kratz K.-L. Occurrence of antibiotics in the aquatic environment. Sci Total Environ 1999, 225:109-118.
74. Holčapek M., Kolářová L., Nobilis M. High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal Bioanal Chem 2008, 391:59-78.
75. Huerta-Fontela M., Galceran M.T., Ventura F. Ultra performance liquid chromatography-tandem mass spectrometry analysis of stimulatory drugs of abuse in wastewater and surface waters. Anal Chem 2007, 79:3821-3829.
76. Huerta-Fontela M., Galceran M.T., Martin-Alons J., Ventura F. Occurrence of psychoactive stimulatory drugs in wastewater in north-eastern Spain. Sci Total Environ 2008, 397:21-40.
77. Huerta-Fontela M., Galceran M.T., Ventura F. Fast liquid chromatography-quadrupole-linear ion trap mass spectrometry for the analysis of pharmaceuticals and hormones in water resources. J Chromatogr A 2010, 1217:4212-4222.
78. Hummel D., Löffler D., Fink G., Ternes T.A. Simultaneous determination of psychoactive drugs and their metabolites in aqueous matrices by liquid chromatography mass spectrometry. Environ Sci Technol 2006, 40:7321-7328.
79. Jiang J.Q., Yin Q., Zhou J.L., Pearce P. Occurrence and treatment trials of endocrine disrupting chemicals EDCs; in wastewaters. Chemosphere 2005, 61:544-550.
80. Jones O.A.H., Voulvoulis N., Lester J.N. Human pharmaceuticals in wastewater treatment processes. Crit Rev Environ Sci Technol 2005, 35:401-427.
81. Kaiser E., Prasse C., Broder K., Ternes T. Transformation of three human metabolites of carbamazepine during sand filtration. SETAC Europe 23rd Annual Meeting, Glasgow 2013.
82. Karthikeyan K.G., Meyer M.T. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci Total Environ 2006, 361:196-207.
83. Kaye C.M., Haddock R.E., Langley P.F., Mellows G., Tasker T.C.G., Greb W.H. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989, 80:60-75.
84. Kazner C., Lehnberg K., Kovalova L., Wintgens T., Melin T., Hollender J., et al. Removal of endocrine disruptors and cytostatics from effluent by nanofiltration in combination with adsorption on powdered activated carbon. Water Sci Technol 2008, 58:1699-1706.
85. Kepp D.R., Sidelmann U.G., Tjornelund J., Hansen S.H. Simultaneous quantitative determination of the major phase I and II metabolites of ibuprofen in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr B Biomed Sci Appl 1997, 696:235-241.
86. Kern S., Baumgartner R., Helbling D.E., Hollender J., Singer H., Loos M.J., et al. A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. J Environ Monit 2012, 12:2100-2111.
87. Khetan S.K., Collins T.J. Human pharmaceuticals in the aquatic environment: a challenge to green chemistry. Chem Rev 2007, 107:2319-2364.
88. 13C nuclear magnetic resonance. Anal Chem 2009, 81:9216-9224.
89. Kormos J.L., Schulz M., Kohler H.-P.E., Ternes T.A. Document biotransformation of selected iodinated X-ray contrast media and characterization of microbial transformation pathways. Environ Sci Technol 2010, 44:4998-5007.
90. Kormos J.L., Schulz M., Ternes T.A. Occurrence of iodinated X-ray contrast media and their biotransformation products in the urban water cycle. Environ Sci Technol 2011, 45:8723-8732.
91. Kosma C.I., Lambropoulou D.A., Albanis T.A. Occurrence and removal of PPCPs in municipal and hospital wastewaters in Greece. J Hazard Mater 2010, 179:804-817.
92. Kosma C.I., Lambropoulou D.A., Albanis T.A. Investigation of PPCPs in wastewater treatment plants in Greece: occurrence, removal and environmental risk assessment. Sci Total Environ 2014, 466-467:421-438.
93. Kosma C.I., Lambropoulou D.A., Albanis T.A. Comprehensive study of the antidiabetic drug metformin and its transformation product guanylurea in Greek wastewaters 2014, [submitted for publication].
94. Krauss M., Singer H., Hollender J. LC-high resolution MS in environmental analysis: from target screening to the identification of unknowns. Anal Bioanal Chem 2010, 397:943-951.
95. Lajeunesse A., Gagnon C., Sauvé S. Determination of basic antidepressants and their N-desmethyl metabolites in raw sewage and wastewater using solid phase extraction and liquid chromatography-tandem mass. Anal Chem 2008, 80:5325-5333.
96. Lambropoulou D.A., Nollet L.M.L. Transformation products of emerging contaminants in the environment: analysis, processes, occurrence, effects and risks 2014, John Wiley and Sons Ltd. 1st ed.
97. Lapworth D.J., Baran N., Stuart M.E., Ward R.S. Emerging organic contaminants in groundwater: a review of sources, fate and occurrence. Environ Pollut 2012, 163:287-303.
98. Leclercq M., Mathieu O., Gomez E., Casellas C., Fenet H., Hillaire-Buys D. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Arch Environ Contam Toxicol 2009, 56:408-415.
99. Lee H.B., Sarafin K., Peart T.E., Svoboda M.L. Acidic pharmaceuticals in sewage - methodology, stability test, occurrence, and removal from Ontario samples. Water Qual Res J Can 2003, 38:667-682.
100. Lee H.B., Peart T.E., Svoboda M.L. Determination of endocrine-disrupting phenols, acidic pharmaceuticals, and personal-care products in sewage by solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr A 2005, 1094:122-129.
101. Lenz K., Mahnik S., Weissenbacher N., Mader R.M., Krenn P., Hann S., et al. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci Technol 2007, 56:141-149.
102. Lertratanangkoon K., Horning M.G. Metabolism of carbamazepine. Drug Metab Dispos 1982, 10:1-10.
103. Letzel M., Weiss K., Schüssler W., Sengl M. Occurrence and fate of the human pharmaceutical metabolite ritalinic acid in the aquatic system. Chemosphere 2010, 81:1416-1422.
104. Leung H.W., Jin L., Wei S., Tsui M.M.P., Zhou B., Jiao L., et al. Pharmaceuticals in tap water: human health risk assessment and proposed monitoring framework in China. Environ Health Perspect 2013, 121:839-846.
105. Li Y., Zhu G., Nq W.J., Tan S.K. A review on removing pharmaceutical contaminants from wastewater by constructed wetlands: design, performance and mechanism. Sci Total Environ 2014, 468-469:908-932.
106. Li Z., Fenet H., Gomez E., Chiron S. Transformation of theantiepileptic drug oxcarbazepine upon different waterdisinfection processes. Water Res 2011, 45:1587-1596.
107. Lin A.Y.C., Tsai Y.T. Occurrence of pharmaceuticals in Taiwan's surface waters: impact of waste streams from hospitals and pharmaceutical production facilities. Sci Total Environ 2009, 407:3793-3802.
108. Lin A.Y.C., Lee W.N., Wang X.H. Ketamine and the metabolite norketamine: persistence and phototransformation toxicity in hospital wastewater and surface water. Water Res 2014, 53:351-360.
109. Lindberg R.H., Wennberg P., Johansson M.I. Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatment plants in Sweden. Environ Sci Technol 2005, 39:3421-3429.
110. Lindstrom M., Buerge I.J., Poiger T., Bergqvist P.-A., Muller M., Buser H.-R. Occurrence and environmental behavior of the bactericide triclosan and its methyl derivative in surface waters and in wastewater. Environ Sci Technol 2002, 36:2322-2329.
111. Lundov M.D., Moesby L., Zachariae C., Johansen J.D. Contamination versus preservation of cosmetics: a review on legislation, usage, infections, and contact allergy. Contact Dermatitis 2009, 60:70-78.
112. Luo Y., Guo W., Ngo H.H., Nghiem L.D., Hai F.I., Zhang J., et al. A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment. Sci Total Environ 2014, 473-474:619-641.
113. Lynn R.K., Smith R.G., Thompson R.M., Deinzer M.L., Griffin D., Gerber N. Characterization of glucuronide metabolites of carbamazepine in human urine by gas chromatography and mass spectrometry. Drug Metab Dispos 1978, 6:494-501.
114. Maggs J.L., Pirmohamed M., Kitteringham N.R., Park B.K. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Drug Metab Dispos 1997, 25:275-280.
115. Marciniec B. Photochemical decomposition of phenazone derivatives. Part 3: kinetics of photolysis in aqueous solutions. Pharmazie 1984, 39:103-106.
116. Martinez-Bueno M.J.M., Uclés S., Hernando M.D., Fernández-Alba A.R. Development of a solvent free method for the simultaneous identification/quantification of drugs of abuse and their metabolites in environmental water by LC-MS/MS. Talanta 2011, 85:157-166.
117. Martinez-Bueno M.J.M., Uclés S., Hernando M.D., Dávoli E., Fernández-Alba A.R. Evaluation of selected ubiquitous contaminants in the aquatic environment and their transformation products. A pilot study of their removal from a sewage treatment plant. Water Res 2011, 45:2331-2341.
118. Maurer H.H., Sauer C., Theobald D.S. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 2006, 28:447-453.
119. McArdell C.S., Molnar E., Suter M.J.F., Giger W. Occurrence and fate of macrolide antibiotics in wastewater treatment plants and in the Glatt Valley Watershed, Switzerland. Environ Sci Technol 2003, 24:5479-5486.
120. McClellan K., Halden R.U. Pharmaceuticals and personal care products in archived U.S. biosolids from the 2001 EPA national sewage sludge survey. Water Res 2010, 44:658-668.
121. 2 and simulated solar irradiation. Water Res 2008, 42:585-594.
122. Metcalfe C.D., Miao X.-S., Koenig B.G., Struger J. Distribution of acidic and neutral drugs in surface water near sewage treatment plants in the lower Great Lakes, Canada. Environ Toxicol Chem 2003, 22:2881-2889.
123. Metcalfe C.D., Chu S., Judt C., Li H., Oakes K.D., Servos M.R., et al. Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environ Toxicol Chem 2010, 29:79-89.
124. Meyer B.K., Ni A., Hu B., Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci 2007, 96:3155-3167.
125. Mezcua M., Gómez M.J., Ferrer I., Aguera A., Hernando M.D., Fernández-Alba A.R. Evidence of 2,7/2,8-dibenzodichloro-p-dioxin as a photodegradation product of triclosan in water and wastewater samples. Anal Chim Acta 2004, 524:241-247.
126. Miao X.S., Metcalfe C.D. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal Chem 2003, 75:3731-3738.
127. Miao X.S., Koenig B.G., Metcalfe C.D. Analysis of acidic drugs in the effluents of sewage treatment plants using liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr A 2002, 952:139-147.
128. Miao X.S., Bishay F., Chen M., Metcalfe C.D. Occurrence of antimicrobials in the final effluents of wastewater treatment plants in Canada. Environ Sci Technol 2004, 38:3533-3541.
129. Miao X.S., Yang J.J., Metcalfe C.D. Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. Environ Sci Technol 2005, 39:7469-7475.
130. Michael I., Vasquez M.I., Hapeshi E., Haddad T., Baginska E., Kummerer K., et al. Metabolites and transformation products of pharmaceuticals in the aquatic environment as contaminants of emerging concern. Transformation products of emerging contaminants in the environment 2014, 413-458. Wiley, UK. D. Lambropoulou, L. Nollet (Eds.).
131. Miège C., Choubert J.M., Ribeiro L., Eusèbe M., Coquery M. Fate of pharmaceuticals and personal care products in wastewater treatment plants - conception of a database and first results. Environ Pollut 2009, 157:1721-1726.
132. Nelson E.D., Do H., Lewis R.S., Carr S.A. Diurnal variability of pharmaceutical, personal care product, estrogen and alkylphenol concentrations in effluent from a tertiary wastewater treatment facility. Environ Sci Technol 2011, 45:1228-1234.
133. Nikolaou A., Meric S., Fatta D. Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal Bioanal Chem 2007, 387:1225-1234.
134. Ohlenbusch G., Kumke M.U., Frimmel F.H. Sorption of phenols to dissolved organic matter investigated by solid phase microextraction. Sci Total Environ 2000, 253:63-74.
135. Ollers S., Singer H.P., Fassler P., Muller S.R. Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at low ng/L level in surface and wastewater. J Chromatogr A 2001, 911:225-234.
136. Olsen B., Munster V.J., Wallensten A., Waldenstrom J., Osterhaus A., Fouchier R.A.M. Global patterns of influenza A virus in wild birds. Science 2006, 312:384-388.
137. Ort C., Lawrence M.G., Reungoat J., Eaglesham Geoff, Carter S., Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res 2010, 44:605-615.
138. Ortiz de García S., Pinto Pinto G., García Encina P., Irusta Mata R. Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain. Sci Total Environ 2013, 444:451-465.
139. Ortiz de García S., Pinto G.P., García-Encina P.A., Mata R.I. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case. J Environ Manage 2013, 129:384-397.
140. Pentikainen P.J., Neuvonen P.J., Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979, 16:195-202.
141. Pérez S., Barceló D. Application of advanced MS techniques to analysis and identification of human and microbial metabolites of pharmaceuticals in the aquatic environment. Trends Anal Chem 2007, 26:494-514.
142. Pérez S., Barceló D. First evidence for occurrence of hydroxylated human metabolites of diclofenac and aceclofenac in wastewater using QqLIT-MS and QqTOF-MS. Anal Chem 2008, 80:8135-8145.
143. Perez-Parada A., Aguera A., Gomez-Ramos M.M., García-Reyes J.F., Heinzen H., Fernandez-Alba R.R. Behavior of amoxicillin in wastewater and river water: identification of its main transformation products by liquid chromatography/electrospray quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2011, 25:731.
144. Petrie B., McAdam E.J., Lester J.N., Cartmell E. Obtaining process mass balances of pharmaceuticals and triclosan to determine their fate during wastewater treatment. Sci Total Environ 2014, 497:553-560.
145. Pieper C., Risse D., Schmidt B., Braun B., Szewzyk U., Rotard W. Water Res 2010, 44:4559.
146. 2: a non-intrusive tool for drug abuse estimation at the community level. TrAC Trends Anal Chem 2008, 27:1053-1069.
147. Postigo C., de Alda M.J.L., Barceló D. Drugs of abuse and their metabolites in the Ebro river basin: occurrence in sewage and surface water, sewage treatment plants removal efficiency, and collective drug usage estimation. Environ Int 2010, 36:75-84.
148. Prasse C., Schlusener M., Schulz R., Ternes T.A. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?. Environ. Sci Technol 2010, 44:1728-1735.
149. Radjenovic J., Perez S., Petrovic M., Barcelo D. Identification and structural characterization of biodegradation products of atenolol and glibenclamide byliquid chromatography coupled to hybrid quadrupole time-offlightand quadrupole ion trap mass spectrometry. J Chromatogr 2008, 1210:142-153.
150. Reddy S., Iden C.R., Brownawell B. Analysis of steroid conjugates in sewage influent and effluent by liquid chromatography-tandem mass spectrometry. Anal Chem 2005, 77:7032-7038.
151. Reith D.M., Appleton D.B., Hooper W., Eadie M.J. The effect of body size on the metabolic clearance of carbamazepine. Biopharm Drug Dispos 2000, 21:103-111.
152. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
153. Ronfeld R.A., Tremaine L.M., Wilner K.D. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997, 32:22-30.
154. Rosal R., Rodríguez A., Perdigón-Melón J.A., Petre A., García-Calvo E., Gómez M.J., et al. Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. Water Res 2010, 44:578-588.
155. Roth H.J., Fenner H. Struktur-Bioreaktivitrat-WirkungsbezogeneEigenschaften 1994, 65-68. Georg Thieme Verlag, Stuttgart. 2nd ed.
156. Routledge E.J., Parker J., Odum J., Ashby J., Sumpter J.P. Some alkyl hydroxy benzoate preservatives parabens; are estrogenic. Toxicol Appl Pharmacol 1998, 153:12-19.
157. Routledge E.J., Sheahan D., Desbrow C., Brighty G.C., Waldock M., Sumpter J.P. Identification of Estrogenic Chemicals in STW Effluent. 2. In Vivo Responses in Trout and Roach. Environ Sci Technol 1998, 32:1559-1565.
158. Rubirola A., Llorca M., Rodriguez-Mozaz S., Casas N., Rodriguez-Roda I., Barceló D., et al. Characterization of metoprolol biodegradation and its transformation products generated in activated sludge batch experiments and in full scale WWTPs. Water Res 2014, 63:21-32.
159. Rule K.L., Ebbett V.R., Vikesland P.J. Formation of chloroform and chlorinated organics by free-chlorine-mediated oxidation of triclosan. Environ Sci Technol 2005, 39:3176-3185.
160. Salgado R., Marques R., Noronha J.P., Mexia J.T., Carvalho G., Oehmen A., et al. Assessing the diurnal variability of pharmaceutical and personal care products in a full-scale activated sludge plant. Environ Pollut 2011, 159:2359-2367.
161. Salgado R., Marques R., Noronha J.P., Carvalho G., Oehmen A., Reis M.A.M. Assessing the removal of pharmaceuticals and personal care products in a full-scale activated sludge plant. Environ Sci Pollut Res 2012, 19:1818-1827.
162. Sammartino M.P., Bellanti F., Castrucci M., Ruiu D., Visco G., Zoccarato T. Ecopharmacology: deliberated or casual dispersion of pharmaceutical principles, phytosanitary, personal health care and veterinary products in environment needs a multivariate analysis or expert systems for the control, the measure and the remediation. Microchem J 2008, 88:201-209.
163. Santos L.H.M.L.M., Araújo A.N., Fachini A., Pena A., Delerue-Matos C., Montenegro M.C.B.S.M. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. J Hazard Mater 2010, 175:45-95.
164. Santos L.H.M.L.M., Gros M., Rodriguez-Mozaz S., Delerue-Matos C., Pena A., Barceló D., et al. Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: identification of ecologically relevant pharmaceuticals. Sci Total Environ 2013, 461-462:302-316.
165. Sawchuk R.J., Maloney J.A., Cartier L.L., Rackley R.J., Chan K.K.H., Lau H.S.L. Analysis of diclofenac and four of its metabolites in human urine by HPLC. Pharm Res 1995, 12:756-762.
166. Schlusener M.P. Fate, pathways and methods for the determination of selected antibiotics and steroid hormones in the environment 2005, [Doctor dissertation], University of Duisburgessen.
167. Schmidt R., Brockmeyer R. Vom Wasser 2002, 98:37-54.
168. Schneider W., Degen P.H. Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection. J Chromatogr A 1981, 217:263-271.
169. Schrey P., Wilhelm M. Rückstände von Arzneimitteln in Wasserproben - Befunde und deren Bewertung aus Sicht der Trinkwasserverordnung. Teil I. DVGW-Schr.reihe. Wasser 1999, 94:1-70.
170. Schroeder D.H. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983, 15:79-781.
171. Schultz M.M., Furlong E.T. Trace analysis of antidepressant pharmaceuticals and their select degradates in aquatic matrixes by LC/ESI/MS/MS. Anal Chem 2008, 80:1756-1761.
172. Schulz M., Löffler D., Wagner M., Ternes T.A. Transformation of the X-ray contrast medium iopromide in soil and biological wastewater treatment. Environ Sci Technol 2008, 42:7207-7217.
173. 14C-oxcarbazepine in man. Xenobiotica 1986, 16:769-778.
174. Schwabe U., Paffrath D. Arzneiverordnungs - report 2008 2008, Springer, Berlin, Heidelberg.
175. Schymanski E.L., Singer H.P., Longrée P., Loos M., Ruff M., Stravs M.A., et al. Strategies to characterize polar organic contamination in wastewater: exploring the capability of high resolution mass spectrometry. Environ Sci Technol 2014, 48:1811-1818.
176. Shackleton R.H.L. J Chromatogr 1986, 91-156.
177. Shao B., Chen D., Zhang J., Wu Y., Sun C. Determination of 76 pharmaceutical drugs by liquid chromatography-tandem mass spectrometry in slaughterhouse wastewater. J Chromatogr A 2009, 1216:8312-8318.
178. Simons J. The $10 billion pill, Fortune magazine 2003.
179. Singer A.C., Howard B.M., Johnson A.C., Knowles C.J., Jackman S., Accinelli C., et al. Meeting report: risk assessment of Tamiflu use under pandemic conditions. Environ Health Perspect 2008, 116:1563-1567.
180. Soni M.G., Carabin I.G., Burdock G.A. Safety assessment of esters of p-hydroxybenzoic acid parabens. Food Chem Toxicol 2013, 43:985-1015.
181. Soufan M., Deborde M., Delmont A., Legube B. Aqueous chlorination of carbamazepine: kinetic study and transformation product identification. Water Res 2013, 47:5076-5087.
182. Stamatis N.K., Konstantinou I.K. Occurrence and removal of emerging pharmaceutical, personal care compounds and caffeine tracer in municipal sewage treatment plant in Western Greece. J Environ Sci Health B 2013, 48:800-813.
183. Stülten D. Occurrence of diclofenac and selected metabolites in sewage effluents. Sci Total Environ 2008, 405:310-316.
184. Stülten D., Lamshöft M., Zühlke S., Spiteller M. Isolation and characterization of a new human urinary metabolite of diclofenac applying LC-NMR-MS and high-resolution mass analyses. J Pharm Biomed Anal 2008, 47:371-376.
185. Stumpf M., Ternes T.A., Haberer K., Baumann W. Isolierung von. Ibuprofen-Metaboliten und deren edeutung als Kontaminanten der aquatischen Umwelt. Vom Wasser 1998, 91:291-303.
186. Suárez S., Carballa M., Omil F., Lema J.M. How are pharmaceutical and personal care products PPCPs; removed from urban wastewaters?. Rev Environ Sci Biotechnol 2008, 7:125-138.
187. Tanaka E., Honda K., Yasuhara H. Ketamine: its pharmacology and toxicology. Jpn J Foren Toxicol 2005, 23:187-191.
188. Terasaki M., Kamata R., Shiraishi F., Makino M. Evaluation of the estrogenic activity of parabens and their chlorinated derivatives by using yeast two-hybrid assay and the enzyme-linked immunosorbent assay. Environ Toxicol Chem 2009, 28:204-208.
189. Terasaki M., Makino M., Tatarazako N. Acute toxicity of parabens and their chlorinated by-products with Daphnia magna and Vibrio fischeri bioassays. J Appl Toxicol 2009, 29:242-247.
190. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 12:3245-3260.
191. Ternes T., Hirsch R. Occurrence and behavior of X-ray contrast media in sewage facilities and the aquatic environment. Environ Sci Technol 2000, 34:2741-2748.
192. Ternes T.A., Stumpf M., Mueller J., Haberer K., Wilken R.-D., Servos M. Behavior and occurrence of estrogens in municipal sewage treatment plants-I. Investigations in Germany, Canada and Brazil. Sci Total Environ 1999, 225:81-90.
193. Ternes T.A., Kreckel P., Mueller J. Behaviour and occurrence of estrogens in municipal sewage treatment plants - II. Aerobic batch experiments with activated sludge. Total Environ 1999, 225:91-99.
194. Ternes T.A., Andersen H., Gilberg D., Bonerz M. Determination of estrogens in sludge and sediments by liquid extraction and GC-MS/MS. Anal Chem 2002, 74:3498-3504.
195. Terzić S., Senta I., Ahel M., Gros M., Petrović M., Barcelo D., et al. Occurrence and fate of emerging wastewater contaminants in Western Balkan Region. Sci Total Environ 2008, 399:66-77.
196. Terzic S., Senta I., Ahel M. Illicit drugs in wastewater of the city of Zagreb Croatia; - estimation of drug abuse in a transition country. Environ Pollut 2010, 158:2686-2693.
197. Thomas P.M., Foster G.D. Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process. Environ Toxicol Chem 2005, 2:25-30.
198. Trautwein C., Kümmerer K. Incomplete degradation of the anti-diabetic Metformin and identification of the microbial dead-end transformation product Guanylurea. Chemosphere 2011, 85:765-773.
199. Tyler C.R., Jobling S., Sumpter J.P. Crit Rev Toxicol 1998, 28:319-361.
200. van Nuijs A.L.N., Pecceu B., Theunis L., Dubois N., Charlier C., Jorens P.G., et al. Cocaine and metabolites in waste and surface water across Belgium. Environ Pollut 2009, 157:123-129.
201. van Nuijs A.L.N., Castiglioni S., Tarcomnicu I., Postigo C., de Alda M.L., Neels H., et al. Illicit drugs consumption estimations derived from wastewater analysis: a critical review. Sci Total Environ 2011, 409:3564-3577.
202. Vanderford B.J., Snyder S.A. Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. Environ Sci Technol 2006, 40:7312-7320.
203. Vasskog T., Anderssen T., Pedersen-Bjergaard S., Kallenborn R., Jensen E. Occurrence of selective serotonin reuptake inhibitors in sewage and receiving waters at Spitsbergen and in Norway. J Chromatogr A 2008, 1185:194-205.
204. Verenitch S.S., Lowe C.J., Mazumder A. Determination of acidic drugs and caffeine in municipal wastewaters and receiving waters by gas chromatography-ion trap tandem mass spectrometry. J Chromatogr A 2006, 1116:193-203.
205. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment - a review. Sci Total Environ 2012, 429:123-155.
206. VICH Environmental impact assessment (EIAs) for veterinary medicinal products (VMPs)-phase I [accessed 11.02.13]. http://www.vichsec.org/pdf/2000/Gl06_st7.pdf.
207. Vieno N.M., Tuhkanen T., Kronberg L. Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. Environ Sci Technol 2005, 39:8220-8226.
208. Vieno N.M., Tuhkanen T., Kronberg L. Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. J Chromatogr A 2006, 1134:101-111.
209. von Bruchhausen F., Dannhardt G., Ebel S., Frahm A.W., Holzgrabe U. Hagers Handbuch der Pharmazeutischen Praxis 1994, vol. 7-9. Springer-Verlag, Berlin. 5th ed.
210. Warrington S.J., Ronfeld R.A., Wilner K.D., Lazar J.D. Human pharmacokinetics of sertraline. Clin Neuropharmacol 1992, 15:54-55.
211. Weigel S., Berger U., Jensen E., Kallenborn R., Thoresen H., Huhnerfuss H. Determination of selected pharmaceuticals and caffeine in sewage and seawater from Tromsø/Norway with emphasis on ibuprofen and its metabolites. Chemosphere 2004, 56:583-592.
212. Weissbrodt D., Kovalova L., Ort C., Pazhepurackel V., Moser R., Hollender J., et al. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environ Sci Technol 2009, 43:810-4817.
213. Wick A., Wagner M., Ternes T.A. Elucidation of the transformation pathway of the opium alkaloid codeine in biological wastewater treatment. Environ Sci Technol 2011, 45:3374-3385.
214. Writer J.H., Ferrer I., Barber L.B., Thurman E.M. Widespread occurrence of neuro-active pharmaceuticals and metabolites in 24 Minnesota rivers and wastewaters. Sci Total Environ 2013, 461-462:519-527.
215. Xiao X.Y., McCalley D.V., McEvoy J. Analysis of estrogens in river water and effluents using solid-phase extraction and gas chromatography-negative chemical ionization mass spectrometry of the pentafluorobenzoyl derivatives. J Chromatogr A 2001, 923:195-204.
216. Xu W., Zhang G., Li X., Zouc S., Lia P., Hua Z., et al. Occurrence and elimination of antibiotics at four sewage treatment plants in the Pearl River Delta PRD; South China. Water Res 2007, 41:4526-4534.
217. Zonja B., Aceña J., Jelic A., Petrovic M., Perez S., Barceló D. Transformation products of emerging contaminants: analytical challenges and future needs, In. Transformation products of emerging contaminants in the environment: analysis, processes, occurrence, effects and risks 2014, 303-320. John Wiley and Sons Ltd. 1st ed. D.A. Lambropoulou, L.M.L. Nollet (Eds.).
218. Zuccato E., Castiglioni S. Illicit drugs in the environment. Philos Trans A Math Phys Eng Sci 2009, 367:3965-3978.
219. Zuccato E., Chiabrando C., Castiglioni S., Calamari D., Bagnati R., Schiarea S., et al. Cocaine in surface water: a new evidence-based tool to monitor community drug abuse. Environ Health Glob 2005, 4:14-20.
220. Zuccato E., Chiabrando C., Castiglioni S., Bagnati R., Fanelli R. Estimating community drug abuse by wastewater analysis. Environ Health Perspect 2008, 116:1027-1032.
221. Zuehlke S., Duennbier U., Heberer T. Determination of polar drug residues in sewage and surface water applying liquid chromatography-tandem mass spectrometry. Anal Chem 2004, 76:6548-6554.
222. Zuehlke S., Duennbier U., Heberer T. Investigation of the behavior and metabolism of pharmaceutical residues during purification of contaminated ground water used for drinking water supply. Chemosphere 2007, 69:1673-1680.
223. Zwiener C., Seeger S., Glauner T., Frimmel F.H. Metabolites from biodegradation of pharmaceutical residues of ibuprofen in biofilm reactors and batch experiments. Anal Bioanal Chem 2002, 372:569-575.